Report Detail

Pharma & Healthcare Global Soft Tissue Sarcoma Targeted Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4681799
  • |
  • 27 February, 2026
  • |
  • Global
  • |
  • 101 Pages
  • |
  • GIR
  • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Soft Tissue Sarcoma Targeted Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Soft Tissue Sarcoma Targeted Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Soft Tissue Sarcoma Targeted Drugs market size and forecasts, in consumption value ($ Million), 2021-2032
Global Soft Tissue Sarcoma Targeted Drugs market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Soft Tissue Sarcoma Targeted Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Soft Tissue Sarcoma Targeted Drugs market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Soft Tissue Sarcoma Targeted Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Soft Tissue Sarcoma Targeted Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Pfizer, Johnson & Johnson, GSK Plc, Teva Pharmaceuticals, Celgene, Bristol Myers Squibb, BeiGene, Shenzhen Chipscreen, Monopar Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Soft Tissue Sarcoma Targeted Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Local Sarcoma
Metastatic Sarcoma
Other Sarcoma
Market segment by Application
Hospitals
Oncology Centers
Other
Market segment by players, this report covers
Roche
Pfizer
Johnson & Johnson
GSK Plc
Teva Pharmaceuticals
Celgene
Bristol Myers Squibb
BeiGene
Shenzhen Chipscreen
Monopar Therapeutics
Akeso Biopharma
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Soft Tissue Sarcoma Targeted Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Soft Tissue Sarcoma Targeted Drugs, with revenue, gross margin, and global market share of Soft Tissue Sarcoma Targeted Drugs from 2021 to 2026.
Chapter 3, the Soft Tissue Sarcoma Targeted Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Soft Tissue Sarcoma Targeted Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Soft Tissue Sarcoma Targeted Drugs.
Chapter 13, to describe Soft Tissue Sarcoma Targeted Drugs research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Soft Tissue Sarcoma Targeted Drugs by Type
    • 1.3.1 Overview: Global Soft Tissue Sarcoma Targeted Drugs Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Soft Tissue Sarcoma Targeted Drugs Consumption Value Market Share by Type in 2025
    • 1.3.3 Local Sarcoma
    • 1.3.4 Metastatic Sarcoma
    • 1.3.5 Other Sarcoma
  • 1.4 Global Soft Tissue Sarcoma Targeted Drugs Market by Application
    • 1.4.1 Overview: Global Soft Tissue Sarcoma Targeted Drugs Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospitals
    • 1.4.3 Oncology Centers
    • 1.4.4 Other
  • 1.5 Global Soft Tissue Sarcoma Targeted Drugs Market Size & Forecast
  • 1.6 Global Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast by Region
    • 1.6.1 Global Soft Tissue Sarcoma Targeted Drugs Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Soft Tissue Sarcoma Targeted Drugs Market Size by Region, (2021-2032)
    • 1.6.3 North America Soft Tissue Sarcoma Targeted Drugs Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Soft Tissue Sarcoma Targeted Drugs Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Soft Tissue Sarcoma Targeted Drugs Market Size and Prospect (2021-2032)
    • 1.6.6 South America Soft Tissue Sarcoma Targeted Drugs Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Roche
    • 2.1.1 Roche Details
    • 2.1.2 Roche Major Business
    • 2.1.3 Roche Soft Tissue Sarcoma Targeted Drugs Product and Solutions
    • 2.1.4 Roche Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Recent Developments and Future Plans
  • 2.2 Pfizer
    • 2.2.1 Pfizer Details
    • 2.2.2 Pfizer Major Business
    • 2.2.3 Pfizer Soft Tissue Sarcoma Targeted Drugs Product and Solutions
    • 2.2.4 Pfizer Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Pfizer Recent Developments and Future Plans
  • 2.3 Johnson & Johnson
    • 2.3.1 Johnson & Johnson Details
    • 2.3.2 Johnson & Johnson Major Business
    • 2.3.3 Johnson & Johnson Soft Tissue Sarcoma Targeted Drugs Product and Solutions
    • 2.3.4 Johnson & Johnson Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Johnson & Johnson Recent Developments and Future Plans
  • 2.4 GSK Plc
    • 2.4.1 GSK Plc Details
    • 2.4.2 GSK Plc Major Business
    • 2.4.3 GSK Plc Soft Tissue Sarcoma Targeted Drugs Product and Solutions
    • 2.4.4 GSK Plc Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 GSK Plc Recent Developments and Future Plans
  • 2.5 Teva Pharmaceuticals
    • 2.5.1 Teva Pharmaceuticals Details
    • 2.5.2 Teva Pharmaceuticals Major Business
    • 2.5.3 Teva Pharmaceuticals Soft Tissue Sarcoma Targeted Drugs Product and Solutions
    • 2.5.4 Teva Pharmaceuticals Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Teva Pharmaceuticals Recent Developments and Future Plans
  • 2.6 Celgene
    • 2.6.1 Celgene Details
    • 2.6.2 Celgene Major Business
    • 2.6.3 Celgene Soft Tissue Sarcoma Targeted Drugs Product and Solutions
    • 2.6.4 Celgene Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Celgene Recent Developments and Future Plans
  • 2.7 Bristol Myers Squibb
    • 2.7.1 Bristol Myers Squibb Details
    • 2.7.2 Bristol Myers Squibb Major Business
    • 2.7.3 Bristol Myers Squibb Soft Tissue Sarcoma Targeted Drugs Product and Solutions
    • 2.7.4 Bristol Myers Squibb Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Bristol Myers Squibb Recent Developments and Future Plans
  • 2.8 BeiGene
    • 2.8.1 BeiGene Details
    • 2.8.2 BeiGene Major Business
    • 2.8.3 BeiGene Soft Tissue Sarcoma Targeted Drugs Product and Solutions
    • 2.8.4 BeiGene Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 BeiGene Recent Developments and Future Plans
  • 2.9 Shenzhen Chipscreen
    • 2.9.1 Shenzhen Chipscreen Details
    • 2.9.2 Shenzhen Chipscreen Major Business
    • 2.9.3 Shenzhen Chipscreen Soft Tissue Sarcoma Targeted Drugs Product and Solutions
    • 2.9.4 Shenzhen Chipscreen Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Shenzhen Chipscreen Recent Developments and Future Plans
  • 2.10 Monopar Therapeutics
    • 2.10.1 Monopar Therapeutics Details
    • 2.10.2 Monopar Therapeutics Major Business
    • 2.10.3 Monopar Therapeutics Soft Tissue Sarcoma Targeted Drugs Product and Solutions
    • 2.10.4 Monopar Therapeutics Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Monopar Therapeutics Recent Developments and Future Plans
  • 2.11 Akeso Biopharma
    • 2.11.1 Akeso Biopharma Details
    • 2.11.2 Akeso Biopharma Major Business
    • 2.11.3 Akeso Biopharma Soft Tissue Sarcoma Targeted Drugs Product and Solutions
    • 2.11.4 Akeso Biopharma Soft Tissue Sarcoma Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Akeso Biopharma Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Soft Tissue Sarcoma Targeted Drugs Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Soft Tissue Sarcoma Targeted Drugs by Company Revenue
    • 3.2.2 Top 3 Soft Tissue Sarcoma Targeted Drugs Players Market Share in 2025
    • 3.2.3 Top 6 Soft Tissue Sarcoma Targeted Drugs Players Market Share in 2025
  • 3.3 Soft Tissue Sarcoma Targeted Drugs Market: Overall Company Footprint Analysis
    • 3.3.1 Soft Tissue Sarcoma Targeted Drugs Market: Region Footprint
    • 3.3.2 Soft Tissue Sarcoma Targeted Drugs Market: Company Product Type Footprint
    • 3.3.3 Soft Tissue Sarcoma Targeted Drugs Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Soft Tissue Sarcoma Targeted Drugs Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Soft Tissue Sarcoma Targeted Drugs Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Soft Tissue Sarcoma Targeted Drugs Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Soft Tissue Sarcoma Targeted Drugs Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Soft Tissue Sarcoma Targeted Drugs Consumption Value by Type (2021-2032)
  • 6.2 North America Soft Tissue Sarcoma Targeted Drugs Market Size by Application (2021-2032)
  • 6.3 North America Soft Tissue Sarcoma Targeted Drugs Market Size by Country
    • 6.3.1 North America Soft Tissue Sarcoma Targeted Drugs Consumption Value by Country (2021-2032)
    • 6.3.2 United States Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Soft Tissue Sarcoma Targeted Drugs Consumption Value by Type (2021-2032)
  • 7.2 Europe Soft Tissue Sarcoma Targeted Drugs Consumption Value by Application (2021-2032)
  • 7.3 Europe Soft Tissue Sarcoma Targeted Drugs Market Size by Country
    • 7.3.1 Europe Soft Tissue Sarcoma Targeted Drugs Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 7.3.3 France Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Soft Tissue Sarcoma Targeted Drugs Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Soft Tissue Sarcoma Targeted Drugs Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Soft Tissue Sarcoma Targeted Drugs Market Size by Region
    • 8.3.1 Asia-Pacific Soft Tissue Sarcoma Targeted Drugs Consumption Value by Region (2021-2032)
    • 8.3.2 China Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 8.3.5 India Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Soft Tissue Sarcoma Targeted Drugs Consumption Value by Type (2021-2032)
  • 9.2 South America Soft Tissue Sarcoma Targeted Drugs Consumption Value by Application (2021-2032)
  • 9.3 South America Soft Tissue Sarcoma Targeted Drugs Market Size by Country
    • 9.3.1 South America Soft Tissue Sarcoma Targeted Drugs Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size by Country
    • 10.3.1 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Soft Tissue Sarcoma Targeted Drugs Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Soft Tissue Sarcoma Targeted Drugs Market Drivers
  • 11.2 Soft Tissue Sarcoma Targeted Drugs Market Restraints
  • 11.3 Soft Tissue Sarcoma Targeted Drugs Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Soft Tissue Sarcoma Targeted Drugs Industry Chain
  • 12.2 Soft Tissue Sarcoma Targeted Drugs Upstream Analysis
  • 12.3 Soft Tissue Sarcoma Targeted Drugs Midstream Analysis
  • 12.4 Soft Tissue Sarcoma Targeted Drugs Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Soft Tissue Sarcoma Targeted Drugs. Industry analysis & Market Report on Soft Tissue Sarcoma Targeted Drugs is a syndicated market report, published as Global Soft Tissue Sarcoma Targeted Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Soft Tissue Sarcoma Targeted Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,480.00
    $5,220.00
    $6,960.00
    2,690.04
    4,035.06
    5,380.08
    3,239.88
    4,859.82
    6,479.76
    531,361.20
    797,041.80
    1,062,722.40
    293,712.00
    440,568.00
    587,424.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report